SG11201408750VA - NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS - Google Patents

NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS

Info

Publication number
SG11201408750VA
SG11201408750VA SG11201408750VA SG11201408750VA SG11201408750VA SG 11201408750V A SG11201408750V A SG 11201408750VA SG 11201408750V A SG11201408750V A SG 11201408750VA SG 11201408750V A SG11201408750V A SG 11201408750VA SG 11201408750V A SG11201408750V A SG 11201408750VA
Authority
SG
Singapore
Prior art keywords
international
bld29
disheng
daxing
bpu
Prior art date
Application number
SG11201408750VA
Inventor
Fei Wang
Zhiguo Xu
Yanping Wang
Yinxiang Wang
Shaojing Hu
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of SG11201408750VA publication Critical patent/SG11201408750VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 January 2014 (03.01.2014) WIPOIPCT (10) International Publication Number WO 2014/000713 A1 (51) International Patent Classification: C07D 401/14 (2006.01) A61K31/4353 (2006.01) C07D 401/12 (2006.01) A61P 35/00 (2006.01) C07D 487/02 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/CN2013/078592 1 July 2013 (01.07.2013) English (30) Priority Data: PCT/CN2012/077924 29 June 2012 (29.06.2012) English CN (71) Applicant: ZHEJIANG BETA PHARMA INCORPOR­ ATION [CN/CN]; 589, Hongfeng RD, Yuhang, Hang- zhou, Zhejiang 311100 (CN). (72) Inventor; and (71) Applicant : HU, Shaojing [US/CN]; Bld29, Zone-B, BPU Software Park, 1 North Disheng St., Business Devel­ opment Area, Daxing, Beijing 100176 (CN). (72) Inventors: WANG, Fei; Bld29, Zone-B, BPU Software Park, 1 North Disheng St., Business Development Area, Daxing, Beijing 100176 (CN). XU, Zhiguo; Bld29, Zone- B, BPU Software Park, 1 North Disheng St., Business De­ velopment Area, Daxing, Beijing 100176 (CN). WANG, Yanping; Bld29, Zone-B, BPU Software Park, 1 North Disheng St., Business Development Area, Daxing, Beijing 100176 (CN). WANG, Yinxiang; Bld29, Zone-B, BPU Software Park, North 1 Disheng St., Business Development Area, Daxing, Beijing 100176 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS m T-H l> o o o (Rs)n R 4 H (I) o CJ (57) Abstract: This invention relates to novel fused quinazoline derivatives of Formula I as c-Met inhibitors, their synthesis and uses for treating c-Met mediated disorders.
SG11201408750VA 2012-06-29 2013-07-01 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS SG11201408750VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2012077924 2012-06-29
PCT/CN2013/078592 WO2014000713A1 (en) 2012-06-29 2013-07-01 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
SG11201408750VA true SG11201408750VA (en) 2015-01-29

Family

ID=49782283

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408750VA SG11201408750VA (en) 2012-06-29 2013-07-01 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS

Country Status (15)

Country Link
US (1) US9617257B2 (en)
EP (1) EP2867223B1 (en)
JP (1) JP6059342B2 (en)
KR (3) KR101726522B1 (en)
AU (1) AU2013283993B2 (en)
BR (1) BR112014032745B1 (en)
CA (1) CA2878049C (en)
ES (1) ES2698511T3 (en)
HK (1) HK1207642A1 (en)
IN (1) IN2015DN00372A (en)
RU (1) RU2619130C2 (en)
SG (1) SG11201408750VA (en)
TW (1) TWI520962B (en)
WO (1) WO2014000713A1 (en)
ZA (1) ZA201500344B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279147A (en) * 2015-05-21 2017-01-04 中国科学院上海药物研究所 A kind of pyrido nitrogen heterocyclic and its production and use
JP6721617B2 (en) 2015-07-20 2020-07-15 ベータ ファーマシューティカルズ カンパニー リミテッド Crystalline forms of maleates of condensed pyridine derivatives and their use
CN106924260B (en) * 2015-12-31 2018-05-25 北京浦润奥生物科技有限责任公司 Purposes of the compound in the drug for treating glioma is prepared
EP3414239A2 (en) 2016-02-05 2018-12-19 Denali Therapeutics Inc. Inhibitors of receptor-interacting protein kinase 1
PL3552017T3 (en) 2016-12-09 2022-08-08 Denali Therapeutics Inc. Compounds useful as ripk1 inhibitors
CN112601752A (en) * 2017-05-26 2021-04-02 伊克诺斯科学公司 Novel inhibitors of MAP4K1
CN110461841B (en) * 2017-06-19 2020-09-15 上海和誉生物医药科技有限公司 Nitrogen heteroaryl derivative with CSF1R inhibitory activity, and preparation method and application thereof
CN109988108B (en) * 2017-12-29 2022-04-29 江苏豪森药业集团有限公司 Preparation method of cabozantinib
EP3893872A4 (en) * 2018-12-14 2022-08-10 Beta Pharma, Inc. Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TWI812302B (en) * 2021-06-24 2023-08-11 南韓商Ｌｇ化學股份有限公司 Novel urea derivative compound as ron inhibitor
EP4289427A1 (en) * 2022-06-10 2023-12-13 Anagenesis Biotechnologies Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005389A2 (en) * 2003-07-07 2005-01-20 Merck Patent Gmbh Malonamide derivatives
DE10357510A1 (en) * 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroaryl-substituted benzenes
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
WO2006014325A2 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
JP5096142B2 (en) * 2004-07-30 2012-12-12 メチルジーン インコーポレイテッド Inhibitors of VEGF receptor and HGF receptor signaling
EP1827434B1 (en) * 2004-11-30 2014-01-15 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
ES2473341T3 (en) * 2005-05-20 2014-07-04 Methylgene Inc Inhibitors of VEGF receptor and HGF receptor signaling
WO2008049855A2 (en) * 2006-10-27 2008-05-02 Glaxo Group Limited 7-azaindole derivatives as c-met kinase inhibitors
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
KR100961410B1 (en) * 2008-10-14 2010-06-09 (주)네오팜 Heterocyclic compounds as protein kinases inhibitors
US8293897B2 (en) * 2008-10-14 2012-10-23 Ning Xi Compounds comprising a spiro-ring and methods of use
CN102086211B (en) 2009-12-08 2013-09-11 广东东阳光药业有限公司 Aromatic heterocyclic compounds serving as protein kinase inhibitor
US9242991B2 (en) * 2010-07-14 2016-01-26 Betta Pharmaceuticals Co., Ltd Substituted fused heterocycles as c-Met tyrosine kinase inhibitors

Also Published As

Publication number Publication date
TWI520962B (en) 2016-02-11
WO2014000713A1 (en) 2014-01-03
CA2878049C (en) 2016-12-13
JP2015521634A (en) 2015-07-30
KR20150031320A (en) 2015-03-23
KR20170017015A (en) 2017-02-14
TW201418254A (en) 2014-05-16
KR101770545B1 (en) 2017-08-22
HK1207642A1 (en) 2016-02-05
RU2015102057A (en) 2016-08-20
ES2698511T3 (en) 2019-02-05
US9617257B2 (en) 2017-04-11
KR101726522B1 (en) 2017-04-12
BR112014032745B1 (en) 2022-01-04
EP2867223A1 (en) 2015-05-06
US20150315210A1 (en) 2015-11-05
EP2867223B1 (en) 2018-09-05
KR20170017014A (en) 2017-02-14
EP2867223A4 (en) 2016-01-06
AU2013283993A1 (en) 2015-02-05
CA2878049A1 (en) 2014-01-03
IN2015DN00372A (en) 2015-06-12
RU2619130C2 (en) 2017-05-12
AU2013283993B2 (en) 2016-07-07
KR101726555B1 (en) 2017-04-12
ZA201500344B (en) 2016-08-31
BR112014032745A2 (en) 2017-06-27
JP6059342B2 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
SG11201408750VA (en) NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201408821SA (en) Selective pi3k delta inhibitors
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201408237YA (en) Compound as wnt signaling inhibitor, composition, and use thereof
SG11201805645QA (en) Lsd1 inhibitors
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201407372UA (en) Nampt inhibitors
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201407988UA (en) Process for improved opioid synthesis
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201408119PA (en) Systems and methods for data center cooling and water desalination
SG11201908114UA (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
SG11201407184PA (en) Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201407591PA (en) Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201901172QA (en) A method for manufacturing a fuel component